|
Title
|
|
|
|
Mast cell–targeting therapies in mast cell activation syndromes
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Purpose of Review Provide an overview of the expanding landscape of mast cell (MC)–targeting treatments in mast cell activation syndromes (MCAS). Recent Findings Tyrosine-kinase inhibitors (TKIs) targeting wild-type and mutated KIT can efficiently induce MC depletion. Avapritinib and midostaurin can also temper IgE-mediated degranulation. Avapritinib has been recently approved by the FDA for the treatment of indolent systemic mastocytosis (ISM). Targeting activation pathways and inhibitory receptors is a promising therapeutic frontier. Recently, the anti Siglec-8 antibody lirentelimab showed promising results in ISM. Summary MCAS is a heterogeneous disorder demanding a personalized therapeutic approach and, especially when presenting as anaphylaxis, has not been formally captured as outcome in prospective clinical trials with TKI. Long-term safety of TKI needs to be addressed. New drugs under investigation in diseases in which non-neoplastic MCs play a pivotal role can provide important inputs to identify new efficient and safe treatments for MCAS. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Current allergy and asthma reports. - Philadelphia, Pa, 2001, currens
Current Allergy and Asthma Reports
|
|
|
Publication
|
|
|
|
Philadelphia, Pa
:
2024
|
|
|
ISSN
|
|
|
|
1529-7322
|
|
|
DOI
|
|
|
|
10.1007/S11882-023-01123-9
|
|
|
Volume/pages
|
|
|
|
24
:2
(2024)
, p. 63-71
|
|
|
ISI
|
|
|
|
001141904500002
|
|
|
Pubmed ID
|
|
|
|
38217824
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|